Acceleron Reports Progress on ALS Drug Candidate

Acceleron Pharma Inc, said that preliminary test results were encouraging for its drug candidate designed to help people with neuromuscular diseases, including ALS. The Cambridge-based company reported preliminary results from a Phase 1 single-dose clinical trial of a drug candidate called ACE-031. The early results indicated that ACE-031 was “safe and well-tolerated at all dose levels and increased lean body mass” said Acceleron Pharma, which added that it has initiated a multiple dose Phase 1 clinical trial for the drug.

Click here to read more.

Share this: